stalled on semaglutide GLP-1 stall: why your weight loss stopped and how to fix it Why switching from tirzepatide to

Available from: Carlsson LMS, Sjholm K, Karlsson C, Jacobson P, Andersson-Assarsson JC, Svensson PA, Larsson I, Hjorth S, Neovius M, Taube M, Carlsson B, Peltonen M (2017) Long-term incidence of microvascular disease after bariatric surgery or usual care in patients with obesity, stratified by baseline glycaemic status: a post-hoc analysis of participants from the Swedish Obese Subjects study

Following the success of the SELECT trial, Wegovy (semaglutide in doses of 1.7 mg and 2.4 mg) received a similar approval in March 2024 for people with overweight or obesity and cardiovascular disease

Animal studies have consistently demonstrated that GLP-1 receptor agonists reduce alcohol intake in rodent models of alcohol consumption

The convenience of taking a tablet under the tongue can lead to better medication adherence, meaning people are more likely to take their medicine as prescribed

Check out this YouTube video to see the pens in action

PLoS One (2022)